New immune cells plus two medications for melanoma that stopped responding to prior treatment

This Phase 1 trial is testing a new combination treatment for advanced melanoma that has stopped responding to standard checkpoint inhibitor therapy. The study combines memory-like natural killer cells—specially engineered immune cells designed to fight cancer—with two medications called nivolumab and relatlimab. Researchers want to learn whether this combination is safe and whether it can help shrink or slow melanoma that has become resistant to prior immunotherapy.

When melanoma stops responding to standard checkpoint inhibitor treatments, patients have limited options. This trial explores whether adding engineered immune cells to the treatment mix might help overcome resistance and offer hope to people whose cancer has progressed despite prior immunotherapy.